Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma

NCT04162158 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT04162158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04162158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma
Lead sponsor
Beijing 302 Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 1, 2019
Completion date
October 1, 2024
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma